StockData
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) stock

STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30178% above fair value
$26.41−0.22 (-0.83%)

Close on Nov 17, 2026Market cap $1.70BP/E –Yield –

Earnings

Stoke Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Jan 11, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$11.30M
+6.6% on a year earlier
EPS, Q3 FY2026
-$1.08
-$0.65 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Stoke Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Jan 11, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Oct 29, 2026after the close$11.30M+6.6%-$1.08Release
Q2 FY2026ended Jun 30, 2026Aug 3, 2026after the close$9.30M–-$0.93Release
Q1 FY2026ended Mar 31, 2026May 7, 2026after the close$6.20M-96.1%-$0.79Release
Q4 FY2025ended Dec 31, 2025Jan 12, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025after the close$10.60M+116.3%-$0.65Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025after the close––-$0.40Release
Q1 FY2025ended Mar 31, 2025May 13, 2025before the open$158.57M+3675.5%$1.90Release
Q4 FY2024ended Dec 31, 2024Mar 18, 2025before the open$22.60M+707.1%–Release
Q3 FY2024ended Sep 30, 2024Nov 5, 2024before the open$4.90M+48.5%-$0.47Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024before the open$4.80M–-$0.46Release
Q1 FY2024ended Mar 31, 2024May 6, 2024before the open$4.20M-19.2%-$0.57Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Stoke Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Stoke Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Stoke Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Results
  5. Update
  6. Results
  7. Update
  8. Results
  9. Results
  10. Results
  11. Update
  12. Update
  13. Update
  14. Results
  15. Results

See a number that looks wrong?